Nippon Shinyaku Co.,Ltd. Logo

Nippon Shinyaku Co.,Ltd.

A research-oriented company developing pharmaceuticals and functional foods.

4516 | T

Overview

Corporate Details

ISIN(s):
JP3717600005
LEI:
Country:
Japan
Address:
京都市南区吉祥院西ノ庄門口町14番地

Description

Nippon Shinyaku Co., Ltd. is a research and development-oriented company operating two main business segments: pharmaceuticals and functional foods. The Pharmaceuticals Division develops, manufactures, and commercializes prescription drugs, focusing on creating new and distinctive medicines for therapeutic areas such as urinary, neurological, respiratory, and circulatory disorders. The Functional Foods Division produces and sells health food products, leveraging the company's expertise and quality standards from its pharmaceutical operations. The company is dedicated to developing original, high-quality products and is pursuing global expansion for its pharmaceutical offerings.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 06:45
確認書
Japanese 8.7 KB
2025-11-14 06:43
半期報告書-第163期(2025/04/01-2026/03/31)
Japanese 233.6 KB
2025-07-04 06:16
臨時報告書
Japanese 27.7 KB
2025-06-24 06:23
確認書
Japanese 8.6 KB
2025-06-24 06:22
内部統制報告書-第162期(2024/04/01-2025/03/31)
Japanese 26.1 KB
2025-06-24 06:18
有価証券報告書-第162期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 02:12
確認書
Japanese 8.6 KB
2024-11-14 02:11
半期報告書-第162期(2024/04/01-2025/03/31)
Japanese 233.5 KB
2024-07-01 04:04
臨時報告書
Japanese 29.3 KB
2024-06-28 04:07
内部統制報告書-第161期(2023/04/01-2024/03/31)
Japanese 23.3 KB
2024-06-28 04:01
確認書
Japanese 8.6 KB
2024-06-28 03:58
有価証券報告書-第161期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2024-02-14 02:06
確認書
Japanese 8.6 KB
2024-02-14 02:05
四半期報告書-第161期第3四半期(2023/10/01-2023/12/31)
Japanese 244.8 KB
2023-11-14 01:59
確認書
Japanese 8.6 KB

Automate Your Workflow. Get a real-time feed of all Nippon Shinyaku Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nippon Shinyaku Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nippon Shinyaku Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.